Certest™ CLIA SARS-CoV-2 Ag Particles

Certest™ CLIA SARS-CoV-2 Ag Particles

CLIA technique is more sensitive that other immunological techniques, which is a great advantage in the rapid and accurate diagnosis of infectious diseases.

Clinically, patients with SARS-CoV-2 infection tend to suffer symptoms such as olfactory and gustatory dysfunction, fever, dry cough, ansomia, fatigue, dyspnoea, headache, diarrhoea and sore throat, followed by vascular and systematic complications. COVID-19 commonly results in pneumoia, which can evolve into acute respiratory distress syndrome, leading to respiratory or multiorgan failure.

On March 11, 2020, the WHO declared the disease a pandemic, due to the high number of infected people and the rapidity of tis spread worldwide.

CerTest CLIA SARS-CoV-2 Ag particles are:

•     Effective and fast. Diagnosis for SARS-CoV-2 will be ready after 15 minutes of reaction.
•     Accurate. CerTest CLIA technology is high accurate, even comparing to high sensitive techniques such as rtPCR.
•     Adaptable to any CLIA analyzer. Flash and Glow reagents are developed for this target, and Bulk format is available under request.

Features

• Assay format: Chemiluminiscence coated magnetic particles
• Method: Qualitative
• Chemiluminescence type: Flash and Glow, both systems available
• Solid phase & conjugate: High specific monoclonals, developed by CerTest Biotec, S.L.
• Label: HRP and acridinium ester label available
• Reagents: Liquid and stable, ready to use

Contents

• CerTest CLIA SARS-CoV-2 Ag 200: References: COV200 , Anti SARS-CoV-2 Beads & Conjugate cartridge (1 unit, 200 determinations), 2 level controls, 4 point calibrator and 2 level controls
• CerTest CLIA Calibration & Control set: References: COVCal, 2 level controls, 4 point calibration
• CerTest CLIA Beads & Conjugate set: References: COVRea , 4 cartridge (800 determinations)
• CerTest CLIA Diluent: References: COVDil , Sample diluent